凝血酶/抗凝血酶复合体(TAT)检测试剂盒(酶联免疫吸附试验法)

ELISA Kit for Thrombin/Antithrombin Complex (TAT)

  • 凝血酶/抗凝血酶复合体(TAT)检测试剂盒(酶联免疫吸附试验法) 产品包装(模拟)
  • 凝血酶/抗凝血酶复合体(TAT)检测试剂盒(酶联免疫吸附试验法) 产品包装(模拟)
  • 凝血酶/抗凝血酶复合体(TAT)检测试剂盒(酶联免疫吸附试验法) 实验结果图
  • SEA831Hu.jpg 标准曲线图
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

特异性

本试剂盒用于检测凝血酶/抗凝血酶复合体(TAT),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。

回收率

分别于定值血清及血浆样本中加入一定量的凝血酶/抗凝血酶复合体(TAT)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。

样本 回收率范围(%) 平均回收率(%)
sodium citrate plasma(n=5) 81-90 86

精密度

精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%

线性

在定值血清及血浆样本内加入适量的凝血酶/抗凝血酶复合体(TAT),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中凝血酶/抗凝血酶复合体(TAT)含量的测定值与理论值的比率。

样本 1:2 1:4 1:8 1:16
sodium citrate plasma(n=5) 94-101% 90-101% 90-104% 90-98%

稳定性

经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。

实验流程

1. 实验前标准品、试剂及样本的准备;
2. 加样(标准品及样本)100µL,37°C孵育1小时;
3. 吸弃,加检测溶液A100µL,37°C孵育1小时;
4. 洗板3次;
5. 加检测溶液B100µL,37°C孵育30分钟;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分钟;
8. 加终止液50µL,立即450nm读数。

实验原理

将凝血酶抗体包被于96孔微孔板中,制成固相载体,向微孔中分别加入标准品或标本,其中的TAT与连接于固相载体上的抗体结合,然后加入生物素化的抗凝血酶Ш抗体,将未结合的生物素化抗体洗净后,加入HRP标记的亲和素,再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的TAT呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值),计算样品浓度。

相关产品

编号 适用物种:Homo sapiens (Human,人) 应用(仅供研究使用,不用于临床诊断!)
SEA831Hu 凝血酶/抗凝血酶复合体(TAT)检测试剂盒(酶联免疫吸附试验法) Enzyme-linked immunosorbent assay for Antigen Detection.

参考文献

杂志 参考文献
IUBMB LIFE Genetic repression of mouse VEGF expression regulates coagulation cascade. [PubMed: 21086498]
Thrombosis Research Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice [ScienceDirect: S0049384811004166]
Journal of Thrombosis and Haemostasis High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality [Wiley: source]
3 Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling [Nature: 20120329]
Am J Respir Cell Mol Bio Prolonged Exposure to Sphingosine 1–Phosphate Receptor-1 Agonists Exacerbates Vascular Leak, Fibrosis, and Mortality after Lung Injury [PubMed: PMC2993087]
PLoS One Host Defense Peptides of Thrombin Modulate Inflammation and Coagulation in Endotoxin-Mediated Shock and Pseudomonas aeruginosa Sepsis [PubMed: PMC3521733]
Haemetology Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India [Pubmed: 23992124]
Am J Transl Res. Selected hemostatic parameters in patients with pancreatic tumors. [Pubmed:Pmc4297344]
PLOS ONE TFPI1 Mediates Resistance to Doxorubicin in Breast Cancer Cells by Inducing a Hypoxic-Like Response [Pubmed:24489651]
Leukemia Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs) [Pubmed:24667943]
Anesthesia &amp; Analgesia Thrombomodulin Improved Liver Injury, Coagulopathy, and Mortality in an Experimental Heatstroke Model in Mice [Pubmed:24781566]
Cell Transplantation Evidence of a Pivotal Role for the Distal Part of the Complement Cascade in the Diurnal Release of Hematopoietic Stem Cells Into Peripheral Blood [Pubmed:26087465]
European Journal of Pharmacology (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coaCavia (Guinea pig )lation [Pubmed:27343380]
J Thromb Haemost. Coagulation factor XI vaccination: an alternative strategy to prevent thrombosis. [pubmed:27813324]
Blood Cells, Inflammation and Infection Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injury [pubmed:29202212]
SCIENCE TRANSLATIONAL MEDICINE Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension [pubmed:28148841]
32 Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target [pubmed:28289017]
留言咨询